TY  - JOUR
T1  - Combined treatment with sertraline and liothyronine in major depression: A randomized, double-blind, placebo-controlled trial
AU  - Cooper-Kazaz R, Apter JT, Cohen R, et al
Y1  - 2007/06/01
N1  - 10.1001/archpsyc.64.6.679
JO  - Archives of General Psychiatry
SP  - 679
EP  - 688
VL  - 64
IS  - 6
N2  - Background 
    Antidepressant treatments that achieve a higher remission rate than those currently available are urgently needed. The thyroid hormone triiodothyronine may potentiate antidepressant effects.Objective 
    To determine the antidepressant efficacy and safety of liothyronine sodium (triiodothyronine) when administered concurrently with the selective serotonin reuptake inhibitor sertraline hydrochloride to patients with major depressive disorder.Design 
    Double-blind, randomized, 8-week, placebo-controlled trial.Setting 
    Outpatient referral centers.Patients 
    A total of 124 adult outpatients meeting unmodified DSM-IV criteria for major depressive disorder without psychotic features.Interventions 
    Patients were randomized to receive sertraline hydrochloride (50 mg/d for 1 week; 100 mg/d thereafter) plus liothyronine sodium (20-25 μg/d for 1 week; 40-50 μg/d thereafter) or sertraline plus placebo for 8 weeks.Main Outcome Measures 
    The primary outcome measure was categorical response to treatment (≥50% decrease in scores on the 21-item Hamilton Rating Scale for Depression from baseline to study end point). Remission rate (final Hamilton Rating Scale for Depression score, ≤6) was a secondary outcome measure.Results 
    Intent-to-treat Hamilton Rating Scale for Depression response rates were 70% and 50% in the sertraline-liothyronine and sertraline-placebo groups, respectively (P = .02; odds ratio, 2.93; 95% confidence interval, 1.23-7.35); remission rates were 58% with sertraline-liothyronine and 38% with sertraline-placebo (P = .02; odds ratio, 2.69; 95% confidence interval, 1.16-6.49). Baseline T3 values were lower in patients treated with sertraline-liothyronine who had remissions than in those without remissions (t48 = 3.36; P<.002). Among patients treated with sertraline-liothyronine, remission was associated with a significant decrease in serum thyrotropin values (F1,73 = 4.00; P<.05). There were no significant effects of liothyronine supplementation on frequency of adverse effects.Conclusions 
    These results demonstrate enhancement of the antidepressant effect of sertraline by concurrent treatment with liothyronine without a significant increase in adverse effects. The antidepressant effect of liothyronine may be directly linked to thyroid function.Trial Registration 
    clinicaltrials.gov Identifier: http://www.clinicaltrials.gov/ct/show/NCT00158990?order=1>NCT00158990
SN  - 0003-990X
M3  - doi: 10.1001/archpsyc.64.6.679
UR  - http://dx.doi.org/10.1001/archpsyc.64.6.679
ER  -